Drug profile · INN
rolapitant hydrochloride
VARUBI
rolapitant hydrochloride (VARUBI) is a neurokinin 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — rolapitant hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
rolapitant hydrochloride (VARUBI) is a neurokinin 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurokinin 1 receptor antagonist
Primary target: Substance-P receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is rolapitant hydrochloride?
rolapitant hydrochloride (VARUBI) is a neurokinin 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rolapitant hydrochloride?
VARUBI is a marketed brand name for rolapitant hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rolapitant hydrochloride?
rolapitant hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.